Does the media favor MAZE or PTCT?

In the previous week, Maze Therapeutics had 3 more articles in the media than PTC Therapeutics. MarketBeat recorded 9 mentions for Maze Therapeutics and 6 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat Maze Therapeutics' score of 0.45 indicating that PTC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PTC Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MAZE or XENE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Maze Therapeutics N/A -34.94% -30.18% Xenon Pharmaceuticals N/A -43.98% -41.72%

Does the media prefer MAZE or XENE?

In the previous week, Maze Therapeutics had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 9 mentions for Maze Therapeutics and 7 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.07 beat Maze Therapeutics' score of 0.45 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LGND or MAZE?

In the previous week, Maze Therapeutics had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 9 mentions for Maze Therapeutics and 8 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.33 beat Maze Therapeutics' score of 0.45 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ligand Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ERAS or MAZE more profitable?

Maze Therapeutics' return on equity of -34.94% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Erasca N/A -38.43% -32.05% Maze Therapeutics N/A -34.94% -30.18%

Does the media favor ERAS or MAZE?

In the previous week, Erasca and Erasca both had 9 articles in the media. Erasca's average media sentiment score of 1.11 beat Maze Therapeutics' score of 0.45 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MAZE or CRSP?

In the previous week, Maze Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 9 mentions for Maze Therapeutics and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat Maze Therapeutics' score of 0.45 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Maze Therapeutics (MAZE) Competitors

$24.60 -0.22 (-0.89%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$24.65 +0.05 (+0.20%)

As of 09/11/2026 07:30 PM Eastern

Compare

MAZE vs. PTCT, XENE, LGND, ERAS, and CRSP

Should you buy Maze Therapeutics stock or one of its competitors? Maze Therapeutics's main competitors and comparable companies include PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), Ligand Pharmaceuticals (LGND), Erasca (ERAS), and CRISPR Therapeutics (CRSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Maze Therapeutics compare to PTC Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and PTC Therapeutics (NASDAQ:PTCT) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

In the previous week, Maze Therapeutics had 3 more articles in the media than PTC Therapeutics. MarketBeat recorded 9 mentions for Maze Therapeutics and 6 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 1.23 beat Maze Therapeutics' score of 0.45 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics presently has a consensus price target of $66.00, indicating a potential upside of 168.29%. PTC Therapeutics has a consensus price target of $98.55, indicating a potential upside of 49.18%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Maze Therapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.64

Maze Therapeutics has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market.

PTC Therapeutics has higher revenue and earnings than Maze Therapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.16	-$131.12M	-$2.52	N/A
PTC Therapeutics	$1.73B	3.19	$682.64M	-$0.58	N/A

Maze Therapeutics has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. Maze Therapeutics' return on equity of -34.94% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
PTC Therapeutics	-3.80%	-362.45%	-1.32%

Summary

Maze Therapeutics beats PTC Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Maze Therapeutics (NASDAQ:MAZE) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Maze Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Maze Therapeutics currently has a consensus price target of $66.00, suggesting a potential upside of 168.29%. Xenon Pharmaceuticals has a consensus price target of $77.13, suggesting a potential upside of 31.51%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Maze Therapeutics had 2 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 9 mentions for Maze Therapeutics and 7 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 1.07 beat Maze Therapeutics' score of 0.45 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.16	-$131.12M	-$2.52	N/A
Xenon Pharmaceuticals	$7.50M	755.96	-$345.91M	-$4.74	N/A

Maze Therapeutics' return on equity of -34.94% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Maze Therapeutics beats Xenon Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Maze Therapeutics compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

Ligand Pharmaceuticals has a net margin of 67.88% compared to Maze Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 20.06% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Maze Therapeutics	N/A	-34.94%	-30.18%

Ligand Pharmaceuticals has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	21.16	$124.45M	$9.35	30.42
Maze Therapeutics	$167.50M	8.16	-$131.12M	-$2.52	N/A

Ligand Pharmaceuticals has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market.

In the previous week, Maze Therapeutics had 1 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 9 mentions for Maze Therapeutics and 8 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 1.33 beat Maze Therapeutics' score of 0.45 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ligand Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Ligand Pharmaceuticals presently has a consensus target price of $335.75, indicating a potential upside of 18.03%. Maze Therapeutics has a consensus target price of $66.00, indicating a potential upside of 168.29%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

Summary

Ligand Pharmaceuticals beats Maze Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Maze Therapeutics compare to Erasca?

Erasca (NASDAQ:ERAS) and Maze Therapeutics (NASDAQ:MAZE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Erasca has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market.

In the previous week, Erasca and Erasca both had 9 articles in the media. Erasca's average media sentiment score of 1.11 beat Maze Therapeutics' score of 0.45 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Erasca currently has a consensus price target of $22.09, indicating a potential upside of 39.11%. Maze Therapeutics has a consensus price target of $66.00, indicating a potential upside of 168.29%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Maze Therapeutics' return on equity of -34.94% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-38.43%	-32.05%
Maze Therapeutics	N/A	-34.94%	-30.18%

Erasca has higher earnings, but lower revenue than Maze Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A
Maze Therapeutics	$167.50M	8.16	-$131.12M	-$2.52	N/A

Summary

Maze Therapeutics beats Erasca on 8 of the 13 factors compared between the two stocks.

How does Maze Therapeutics compare to CRISPR Therapeutics?

Maze Therapeutics (NASDAQ:MAZE) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Maze Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-34.94%	-30.18%
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%

Maze Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 168.29%. CRISPR Therapeutics has a consensus target price of $68.06, indicating a potential upside of 31.58%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Maze Therapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	3 Strong Buy rating(s)	3.08
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61

In the previous week, Maze Therapeutics had 1 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 9 mentions for Maze Therapeutics and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat Maze Therapeutics' score of 0.45 indicating that CRISPR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.3% of Maze Therapeutics shares are held by insiders. Comparatively, 5.2% of CRISPR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maze Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Maze Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.16	-$131.12M	-$2.52	N/A
CRISPR Therapeutics	$3.51M	1,424.73	-$581.60M	-$4.76	N/A

Summary

Maze Therapeutics beats CRISPR Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.37B	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-9.76	8.38	214.57	20.80
Price / Sales	8.16	1,378.81	633.76	90.54
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	3.33	15.12	10.33	6.20
Net Income	-$131.12M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-6.14%	-4.34%	-3.32%	-2.35%
1 Month Performance	-10.64%	-0.02%	-0.41%	-2.77%
1 Year Performance	5.58%	40.64%	19.21%	7.63%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	2.4441 of 5 stars	$24.60 -0.9%	$66.00 +168.3%	-0.8%	$1.37B	$167.50M	N/A	141	Insider Trade High Trading Volume
PTCT PTC Therapeutics	3.7602 of 5 stars	$69.30 -2.9%	$98.55 +42.2%	+8.4%	$5.78B	$1.73B	N/A	1,410	Positive News Insider Trade
XENE Xenon Pharmaceuticals	2.5197 of 5 stars	$59.75 -1.1%	$77.13 +29.1%	+57.6%	$5.78B	$7.50M	N/A	210	Positive News
LGND Ligand Pharmaceuticals	3.9676 of 5 stars	$285.60 -1.4%	$335.75 +17.6%	+70.3%	$5.69B	$290.54M	30.55	80	Insider Trade
ERAS Erasca	2.427 of 5 stars	$16.19 -0.4%	$22.09 +36.4%	+886.3%	$5.66B	N/A	N/A	120	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. PTCT, XENE, LGND, ERAS, and CRSP

How does Maze Therapeutics compare to PTC Therapeutics?

Summary

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Summary

How does Maze Therapeutics compare to Ligand Pharmaceuticals?

Summary

How does Maze Therapeutics compare to Erasca?

Summary

How does Maze Therapeutics compare to CRISPR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. PTCT, XENE, LGND, ERAS, and CRSP

How does Maze Therapeutics compare to PTC Therapeutics?

Does the media favor MAZE or PTCT?

Do analysts rate MAZE or PTCT?

Which has more risk and volatility, MAZE or PTCT?

Which has higher valuation and earnings, MAZE or PTCT?

Is MAZE or PTCT more profitable?

Summary

How does Maze Therapeutics compare to Xenon Pharmaceuticals?

Which has more risk and volatility, MAZE or XENE?

Do analysts prefer MAZE or XENE?

Does the media prefer MAZE or XENE?

Which has better valuation & earnings, MAZE or XENE?

Is MAZE or XENE more profitable?

Do insiders & institutionals have more ownership in MAZE or XENE?

Summary

How does Maze Therapeutics compare to Ligand Pharmaceuticals?

Is LGND or MAZE more profitable?

Which has preferable valuation & earnings, LGND or MAZE?

Which has more risk & volatility, LGND or MAZE?

Does the media prefer LGND or MAZE?

Do insiders and institutionals believe in LGND or MAZE?

Do analysts prefer LGND or MAZE?

Summary

How does Maze Therapeutics compare to Erasca?

Which has more risk and volatility, ERAS or MAZE?

Does the media favor ERAS or MAZE?

Do analysts prefer ERAS or MAZE?

Do insiders & institutionals believe in ERAS or MAZE?

Is ERAS or MAZE more profitable?

Which has stronger earnings and valuation, ERAS or MAZE?

Summary

How does Maze Therapeutics compare to CRISPR Therapeutics?

Is MAZE or CRSP more profitable?

Do analysts recommend MAZE or CRSP?

Does the media refer more to MAZE or CRSP?

Do insiders & institutionals believe in MAZE or CRSP?

Which has more risk & volatility, MAZE or CRSP?

Which has stronger earnings & valuation, MAZE or CRSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools